09.05.2012 | Diagnostics
Aspirin and non-aspirin non-steroidal anti-inflammatory drug use and risk of lung cancer

Publication year: 2012Source:Lung CancerWei-Yen Lim, Khoon Leong Chuah, Philip Eng, Swan Swan Leong, Elaine Lim, Tow Keang Lim, Alan Ng, Wee Teng Poh, Augustine Tee, Ming Teh, Agus Salim, Adeline Seow There is evidence that aspirin and non-aspirin non-steroidal anti-inflammatory drug (NSAID) have anti-carcinogenic properties, but their effect on lung cancer, in particular in never-smokers, is unclear. Information on past or current use of anti-inflammatory medication was obtained in 398

Read More 5 0

09.05.2012 | Locally Advanced Disease
Are postoperative consequences of neoadjuvant chemotherapy for non-small cell lung cancer more severe in elderly patients?

Publication year: 2012Source:Lung Cancer, Volume 76, Issue 2Caroline Rivera, Jacques Jougon, Marcel Dahan, Pierre-Emmanuel Falcoz, Alain Bernard, Laurent Brouchet Objectives The purpose of this study was to assess the postoperative morbidity of patients

Read More 3 0

08.05.2012 | Early Disease
Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence [ORIGINAL ARTICLES: GENERAL THORACIC]

Background This study characterizes the management of locoregional recurrence (LRR) in patients with high-risk stage I non-small cell lung cancer (NSCLC) treated with lung radiofrequency ablation (RFA). Methods Consecutive patients with biopsy-proven stage I NSCLC underwent computed tomography-guided lung RFA from December 2003 to 2010. All patients were deemed medically inoperable or refused an operation. RFA was performed with curative intent. Results Fifty-five ablations were performed in 45

Read More 4 0

08.05.2012 | Early Disease
Fusion Positron Emission/Computed Tomography Underestimates the Presence of Hilar Nodal Metastases in Patients With Resected Non-Small Cell Lung Cancer [ORIGINAL ARTICLES: GENERAL THORACIC]

Background The 5-year survival for patients with resected stage II (N1) non-small cell lung cancer ranges from 40% to 55%. No data exist addressing the benefit of neoadjuvant therapy for patients with stage II disease. This is largely in part due to the lack of a reliable, minimally invasive method to assess hilar nodes. This study is aimed at determining the ability of fusion positron emission/computed tomography (PET/CT) to identify hilar metastases in patients with resected non-small cell lung

Read More 4 0

08.05.2012 | Early Disease
Human Immunodeficiency Virus Infection as a Prognostic Factor in Surgical Patients With Non-Small Cell Lung Cancer [ORIGINAL ARTICLES: GENERAL THORACIC]

Background The purpose of this study was to assess the effect of human immunodeficiency virus (HIV) infection on postoperative survival among non-small cell lung cancer (NSCLC) patients. Methods A retrospective cohort study compared 22 HIV-infected lung cancer patients to 2,430 lung cancer patients with HIV-unspecified status who underwent resection at Johns Hopkins Hospital from 1985 to 2009. Subcohort comparative analyses were performed using individual matching methods. Results Thirty-day

Read More 3 0